Hasil Pencarian - David A Cameron

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer

    On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer oleh Richard J. Bownes, Arran K. Turnbull, Carlos Martinez-Perez, David A. Cameron, Andrew H. Sims, Olga Oikonomidou

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregivers

    The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with ca... oleh Ruth I. Hart, David A. Cameron, Fiona J. Cowie, Jeni Harden, Nicholas B. Heaney, David Rankin, Angela B. Jesudason, Julia Lawton

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

    Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resul... oleh Louise Hiller, Janet A. Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L. Howe, David A. Cameron, David Miles, Andrew M. Wardley, Helena M. Earl

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model oleh Kate M. Moore, Vera Cerqueira, Kenneth G. MacLeod, Peter Mullen, Richard L. Hayward, Simon Green, David J. Harrison, David A. Cameron, Simon P. Langdon

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

    OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer oleh Robert C Stein, Janet A Dunn, John MS Bartlett, Amy F Campbell, Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny L Donovan, Christopher McCabe, Luke Hughes-Davies, Andreas Makris, on behalf of the OPTIMA Trial Management Group

    Diterbitkan 2016-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

    Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT oleh Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: